Maxim Group Upgrades Galmed Pharmaceuticals (GLMD) to Buy
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Price: $0.57 +1.79%
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Galmed Pharmaceuticals (NASDAQ: GLMD) from Hold to Buy with a price target of $4.00.
For an analyst ratings summary and ratings history on Galmed Pharmaceuticals click here. For more ratings news on Galmed Pharmaceuticals click here.
Shares of Galmed Pharmaceuticals closed at $1.15 yesterday.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- JPMorgan Upgrades Akamai Technologies (AKAM) to Neutral 'on Account of Confidence in Revenue Reacceleration'
- JPMorgan Upgrades Kolmar Korea Co Ltd (161890:KS) to Overweight
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
